Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

17.12.24 22:15 Uhr

Werte in diesem Artikel

DUBLIN, Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business update on Tuesday, January 14, 2025, at 9:45 a.m. PST / 5:45 p.m. GMT.

A live audio webcast of the presentation may be accessed via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be available on the website for 30 days following the conference.  

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Investors:
Jeff Macdonald
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com     
Ireland, +353 1 634 3211
U.S., +1 650 496 2717

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland, +353 1 637 2141
U.S., +1 215 867 4948

Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302334228.html

SOURCE Jazz Pharmaceuticals plc

Ausgewählte Hebelprodukte auf Jazz Pharmaceuticals

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Jazz Pharmaceuticals

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Jazz Pharmaceuticals PLC

Analysen zu Jazz Pharmaceuticals PLC

DatumRatingAnalyst
11.06.2019Jazz Pharmaceuticals OverweightBarclays Capital
14.12.2018Jazz Pharmaceuticals Peer PerformWolfe Research
08.11.2018Jazz Pharmaceuticals BuyB. Riley FBR
08.08.2018Jazz Pharmaceuticals BuyStifel, Nicolaus & Co., Inc.
23.03.2018Jazz Pharmaceuticals NeutralH.C. Wainwright & Co.
DatumRatingAnalyst
11.06.2019Jazz Pharmaceuticals OverweightBarclays Capital
08.11.2018Jazz Pharmaceuticals BuyB. Riley FBR
08.08.2018Jazz Pharmaceuticals BuyStifel, Nicolaus & Co., Inc.
08.11.2017Jazz Pharmaceuticals OutperformRBC Capital Markets
19.10.2017Jazz Pharmaceuticals BuyFBR & Co.
DatumRatingAnalyst
14.12.2018Jazz Pharmaceuticals Peer PerformWolfe Research
23.03.2018Jazz Pharmaceuticals NeutralH.C. Wainwright & Co.
05.12.2017Jazz Pharmaceuticals NeutralMizuho
10.11.2017Jazz Pharmaceuticals NeutralH.C. Wainwright & Co.
25.08.2017Jazz Pharmaceuticals NeutralH.C. Wainwright & Co.
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Jazz Pharmaceuticals PLC nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"